Share-based Payment Arrangement, Expense of Vanda Pharmaceuticals Inc. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vanda Pharmaceuticals Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • Vanda Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,112,000, a 30% decline year-over-year.
  • Vanda Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $10,052,000, a 22% decline year-over-year.
  • Vanda Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2024 was $12,432,000, a 11% decline from 2023.
  • Vanda Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $14,040,000, a 14% decline from 2022.
  • Vanda Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $16,279,000, a 5.9% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Vanda Pharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $10,052,000 $2,112,000 -$887,000 -30% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $10,939,000 $2,106,000 -$880,000 -29% 01 Apr 2025 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $11,819,000 $2,971,000 -$613,000 -17% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $12,432,000 $2,863,000 -$410,000 -13% 01 Oct 2024 31 Dec 2024 10-K 14 Feb 2025 2024 FY
Q3 2024 $12,842,000 $2,999,000 -$168,000 -5.3% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025 2025 Q3
Q2 2024 $13,010,000 $2,986,000 -$263,000 -8.1% 01 Apr 2024 30 Jun 2024 10-Q 31 Jul 2025 2025 Q2
Q1 2024 $13,273,000 $3,584,000 -$767,000 -18% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $14,040,000 $3,273,000 -$510,000 -13% 01 Oct 2023 31 Dec 2023 10-K 14 Feb 2025 2024 FY
Q3 2023 $14,550,000 $3,167,000 -$721,000 -19% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $15,271,000 $3,249,000 -$581,000 -15% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $15,852,000 $4,351,000 -$427,000 -8.9% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $16,279,000 $3,783,000 +$9,000 +0.24% 01 Oct 2022 31 Dec 2022 10-K 14 Feb 2025 2024 FY
Q3 2022 $16,270,000 $3,888,000 -$63,000 -1.6% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $16,333,000 $3,830,000 +$90,000 +2.4% 01 Apr 2022 30 Jun 2022 10-Q 28 Jul 2023 2023 Q2
Q1 2022 $16,243,000 $4,778,000 +$869,000 +22% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $15,374,000 $3,774,000 +$562,000 +17% 01 Oct 2021 31 Dec 2021 10-K 08 Feb 2024 2023 FY
Q3 2021 $14,812,000 $3,951,000 +$816,000 +26% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $13,996,000 $3,740,000 +$671,000 +22% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $13,325,000 $3,909,000 -$35,000 -0.89% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $13,360,000 $3,212,000 -$456,000 -12% 01 Oct 2020 31 Dec 2020 10-K 09 Feb 2023 2022 FY
Q3 2020 $13,816,000 $3,135,000 -$272,000 -8% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $14,088,000 $3,069,000 -$32,000 -1% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 $14,120,000 $3,944,000 +$662,000 +20% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $13,458,000 $3,668,000 +$746,000 +26% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $12,712,000 $3,407,000 +$535,000 +19% 01 Jul 2019 30 Sep 2019 10-Q 29 Oct 2020 2020 Q3
Q2 2019 $12,177,000 $3,101,000 +$380,000 +14% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $11,797,000 $3,282,000 +$131,000 +4.2% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $11,666,000 $2,922,000 +$140,000 +5% 01 Oct 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
Q3 2018 $11,526,000 $2,872,000 +$101,000 +3.6% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $11,425,000 $2,721,000 +$65,000 +2.4% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $11,360,000 $3,151,000 +$895,000 +40% 01 Jan 2018 31 Mar 2018 10-Q 03 May 2019 2019 Q1
Q4 2017 $10,465,000 $2,782,000 +$679,000 +32% 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
Q3 2017 $9,786,000 $2,771,000 +$671,000 +32% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $9,115,000 $2,656,000 +$582,000 +28% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $8,533,000 $2,256,000 -$10,000 -0.44% 01 Jan 2017 31 Mar 2017 10-Q 02 May 2018 2018 Q1
Q4 2016 $8,543,000 $2,103,000 +$216,000 +11% 01 Oct 2016 31 Dec 2016 10-K 19 Feb 2019 2018 FY
Q3 2016 $8,327,000 $2,100,000 +$39,000 +1.9% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $8,288,000 $2,074,000 +$6,000 +0.29% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $8,282,000 $2,266,000 +$321,000 +17% 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1
Q4 2015 $7,961,000 $1,887,000 +$217,000 +13% 01 Oct 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
Q3 2015 $7,744,000 $2,061,000 +$650,000 +46% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $7,094,000 $2,068,000 +$625,000 +43% 01 Apr 2015 30 Jun 2015 10-Q 28 Jul 2016 2016 Q2
Q1 2015 $6,469,000 $1,945,000 +$591,000 +44% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016 2016 Q1
Q4 2014 $5,878,000 $1,670,000 +$213,000 +15% 01 Oct 2014 31 Dec 2014 10-K 17 Feb 2017 2016 FY
Q3 2014 $5,665,000 $1,411,000 -$125,000 -8.1% 01 Jul 2014 30 Sep 2014 10-Q 04 Nov 2015 2015 Q3
Q2 2014 $5,790,000 $1,443,000 +$336,000 +30% 01 Apr 2014 30 Jun 2014 10-Q 31 Jul 2015 2015 Q2
Q1 2014 $5,454,000 $1,354,000 +$50,000 +3.8% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015 2015 Q1
Q4 2013 $5,404,000 $1,457,000 -$414,000 -22% 01 Oct 2013 31 Dec 2013 10-K 12 Feb 2016 2015 FY
Q3 2013 $5,818,000 $1,536,000 +$960,000 +167% 01 Jul 2013 30 Sep 2013 10-Q 27 Oct 2014 2014 Q3
Q2 2013 $4,858,000 $1,107,000 -$81,000 -6.8% 01 Apr 2013 30 Jun 2013 10-Q 08 Aug 2014 2014 Q2
Q1 2013 $4,939,000 $1,304,000 -$87,000 -6.3% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014 2014 Q1
Q4 2012 $5,026,000 $1,871,000 01 Oct 2012 31 Dec 2012 10-K 13 Mar 2015 2014 FY
Q3 2012 $576,000 -$686,000 -54% 01 Jul 2012 30 Sep 2012 10-Q 08 Nov 2013 2013 Q3
Q2 2012 $1,188,000 -$126,000 -9.6% 01 Apr 2012 30 Jun 2012 10-Q 31 Jul 2013 2013 Q2
Q1 2012 $1,391,000 01 Jan 2012 31 Mar 2012 10-Q 10 May 2013 2013 Q1
Q3 2011 $1,262,000 01 Jul 2011 30 Sep 2011 10-Q 08 Nov 2012 2012 Q3
Q2 2011 $1,314,000 01 Apr 2011 30 Jun 2011 10-Q 03 Aug 2012 2012 Q2

Vanda Pharmaceuticals Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $12,432,000 -$1,608,000 -11% 01 Jan 2024 31 Dec 2024 10-K 14 Feb 2025 2024 FY
2023 $14,040,000 -$2,239,000 -14% 01 Jan 2023 31 Dec 2023 10-K 14 Feb 2025 2024 FY
2022 $16,279,000 +$905,000 +5.9% 01 Jan 2022 31 Dec 2022 10-K 14 Feb 2025 2024 FY
2021 $15,374,000 +$2,014,000 +15% 01 Jan 2021 31 Dec 2021 10-K 08 Feb 2024 2023 FY
2020 $13,360,000 -$98,000 -0.73% 01 Jan 2020 31 Dec 2020 10-K 09 Feb 2023 2022 FY
2019 $13,458,000 +$1,792,000 +15% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $11,666,000 +$1,201,000 +11% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $10,465,000 +$1,922,000 +22% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $8,543,000 +$582,000 +7.3% 01 Jan 2016 31 Dec 2016 10-K 19 Feb 2019 2018 FY
2015 $7,961,000 +$2,083,000 +35% 01 Jan 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
2014 $5,878,000 +$474,000 +8.8% 01 Jan 2014 31 Dec 2014 10-K 17 Feb 2017 2016 FY
2013 $5,404,000 +$378,000 +7.5% 01 Jan 2013 31 Dec 2013 10-K 12 Feb 2016 2015 FY
2012 $5,026,000 -$460,000 -8.4% 01 Jan 2012 31 Dec 2012 10-K 13 Mar 2015 2014 FY
2011 $5,486,000 +$679,000 +14% 01 Jan 2011 31 Dec 2011 10-K 25 Feb 2014 2013 FY
2010 $4,807,000 01 Jan 2010 31 Dec 2010 10-K 26 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.